Back HCV Treatment

HCV Treatment

Daclatasvir + Sofosbuvir Shows High Hep C Cure Rate, New Studies Underway

A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of Medicine. A series of new studies of this combination in difficult-to-treat groups including HIV/HCV coinfected people and liver transplant recipients are underway.

alt

Read more:

Daclatasvir + VX-135 May Cure 80% of Genotype 1 Hepatitis C Patients

An all-oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) NS4A inhibitor daclatasvir plus Vertex's experimental nucleotide polymerase inhibitor VX-135 -- without interferon or ribavirin -- produced early sustained virological response at 4 weeks post-treatment in 83% of previously untreated genotype 1 patients in a small study, Vertex announced this week.

alt

Read more:

FDA Approves Sofosbuvir (Sovaldi) for Hepatitis C Genotypes 1, 2, 3, and 4

The U.S. Food and Drug Administration on Friday approved the first hepatitis C virus (HCV) polymerase inhibitor, sofosbuvir, to be marketed by Gilead Sciences under the brand name Sovaldi. Sofosbuvir was approved for use with ribavirin for people with HCV genotypes 2 or 3 -- making it the first-ever interferon-free hepatitis C treatment -- and in combination with pegylated interferon/ribavirin for people with harder-to-treat HCV genotypes 1 or 4.

alt

Read more:

AbbVie Combo Cures 96% of Treatment-experienced Hepatitis C Patients

A 4-drug regimen containing 3 AbbVie direct-acting antivirals plus ribavirin produced sustained virological response in 96% of chronic hepatitis C patients without cirrhosis who were previously treated unsuccessfully with pegylated interferon and ribavirin, with similar response rates for HCV genotypes 1a and 1b, the company announced.

alt

Read more:

Sofosbuvir/Ledipasvir Cures More than 90% of Genotype 1 Hepatitis C

Gilead Sciences this week announced sustained virological response rates from the Phase 3 ION trials testing a combination pill containing its newly approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir. Across the 3 studies, sofosbuvir/ledipasvir taken for 8 or 12 weeks cured more than 90% of treatment-naive and treatment-experienced genotype 1 patients.

alt

Read more: